Partner Courtenay Brinckerhoff was quoted in a BioWorld article, “With BPCIA Dance Optional, Next Moves Up to Biosimilar Sponsors,” on July 24, 2015. The article discussed next steps for biosimilar sponsors after the Federal Circuit confirmed that the Biologic Price Competition and Innovation Act’s intricate patent information exchange is optional. Brinckerhoff said it’s likely that many biosimilar developers will choose not to follow the steps in place by BPCIA since it requires the biosimilar sponsor to give a copy of its application and other confidential manufacturing-related information to the reigning market champion.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”